Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: J Invest Dermatol. 2013 Mar 8;133(8):2050–2058. doi: 10.1038/jid.2013.114

Figure 3. Melanoma-specific survival in stage III and stage IV melanoma(TMA) Patients.

Figure 3

A: Representative TMA IHC staining of B7-H3. (A1) LN metastasis with absent expression of B7-H3. (A2) LN metastasis with weak expression of B7-H3. (A3) LN metastasis with moderate expression of B7-H3. (A4) LN metastasis with strong expression of B7-H3. In Figure A1, A2, A3 and A4, scale bars indicate 200μm in length. Magnification: 100X. B: Stage III TMA(n=139) MSS comparing B7-H3 IHC score of 0-1(no-weak) versus 2-3(moderate-strong). C: Stage IV TMA(n=169) MSS comparing B7-H3 IHC score of 0-2(no-moderate) versus 3(strong). D: Analysis of B7-H3 IHC score between paired matched stage III LN metastases and stage IV distant metastases from the same patient in the stage IV TMA. Horizontal lines represent average B7-H3 score among each stage.